- Active not recruitingPHASE3
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has spread and has a specific gene change (BRAF). It compares these new combinations with standard chemotherapy to see which works best for people who haven't had treatment for their spread cancer.
For: NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
Personalized Medicine for Advanced Biliary Cancer Patients
This study looks at whether adding a special "targeted" drug after initial treatment for advanced bile duct cancer works better than continuing standard treatment. It customises treatment based on your tumour's unique features.
For: Biliary Tract NeoplasmsBelgium · France · United Kingdom - Active not recruitingPHASE2
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at combining three medicines for advanced bowel cancer that has spread. It compares a new combination therapy (encorafenib, cetuximab, and pembrolizumab) with pembrolizumab alone for patients who haven't had treatment yet and have specific gene changes.
For: Metastatic Colorectal CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
This study is looking at three new medicines for advanced melanoma, a type of skin cancer. It aims to see if combining these medicines helps people with melanoma that has spread and has a specific gene change called 'BRAF'.
For: MelanomaUnited States · Argentina · Austria - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Z0011001-A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF ZN-c3 ADMINISTERED IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN ADULTS WITH METASTATIC COLORECTAL CANCER
This study is testing a new combination of medicines for people with bowel cancer that has spread. We want to see if a new drug called Azenosertib, given with two existing drugs (Encafenib and Cetuximab), is safe and helps shrink the cancer. This is an early-stage study.
For: metastatic colorectal cancerPoland · Spain · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
C4221023 - A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY
This study is looking at new drug combinations for people with a certain type of advanced melanoma that has not responded to previous treatment. It compares two groups of medicines to see which works better at shrinking the cancer.
For: Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanomaSpain · Germany · Slovakia - Ongoing, recruitingTherapeutic exploratory (Phase II)
C4221008 - A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Non-small Cell Lung Cancer
This study is looking at two drugs, encorafenib and binimetinib, for a type of lung cancer called non-small cell lung cancer. It's for patients whose cancer has a specific change called a BRAFV600 mutation. Researchers want to see how well these drugs shrink the cancer.
For: Non-small Cell Lung CancerNetherlands · Spain · Italy - Ongoing, recruitingTherapeutic use (Phase IV)
Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melanoma receiving treatment with Encorafenib + Binimetinib
This study looks at how well different treatments like surgery or radiotherapy work for people with a specific type of advanced melanoma. They are already taking two medicines, Encorafenib and Binimetinib, and researchers want to see if adding these other treatments helps them live longer without their cancer growing.
For: Unresectable or metastatic melanoma with a BRAF V600 mutation (inoperable stage III or metastatic stage IV)Germany